<DOC>
	<DOCNO>NCT01528826</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety vinorelbine plus oxaliplatin pretreated metastatic triple-negative breast cancer .</brief_summary>
	<brief_title>Salvage Chemotherapy Vinorelbine Plus Oxaliplatin Metastatic Triple-negative Breast Cancer : Prospective Trial</brief_title>
	<detailed_description>Triple-negative breast cancer associate less treatment choice shorter overall survival . Both vinorebine oxaliplatin effective metastatic breast cancer . The investigator design trial evaluate combination two drug pretreated metastatic triple-negative breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Females age 18 70 year old 2 . ECOG performance 02 3 . Life expectancy 3 month 4 . Histological proven unresectable recurrent advance breast cancer 5 . Triplenegative estrogen receptor ( ER ) , progestogen receptor ( PR ) , human epithelial receptor2 ( HER2 ) immunohistochemistry ( IHC ) test . For patient ER negative , PR negative , Her2 two plus , negative Her2 gene amplification verify FISH test . Her2 one plus may consider FISH verification . 6 . No 2 chemotherapy metastatic breast cancer . 7 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST1.1 ) 8 . No anticancer therapy within 4 week 9 . No neuropathy grade I 10 . Adequate hematologic , hepatic , renal function , No serious medical history heart , lung , liver kidney 11 . Provision write informed consent prior study specific procedures 1 . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) 2 . Women childbearing potential , unwilling use adequate contraceptive protection course study 3 . Treatment investigational product within 4 week first treatment 4 . Symptomatic central nervous system metastases 5 . Other active malignancy ( include hematologic malignancy ) malignancy , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia . 6 . Patient history clinically significant cardiovascular , hepatic , respiratory renal disease , clinically significant hematological endocrinal abnormality , clinically significant neurological psychiatric condition 7 . Uncontrolled serious infection 8 . Previous administration vinorelbine 9 . Patients bad compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>metastatic triple-negative breast cancer</keyword>
	<keyword>vinorebine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>